Home » Hepatic Encephalopathy Therapeutics Market

Hepatic Encephalopathy Therapeutics Market – Growth, Future Prospects & Competitive Analysis, 2018-2026

Price: $4999

Published: | Report ID: 6620 | Report Format : PDF

Market Insights

As per the citing of the National Organization for Rare Diseases (NORD) 2016 report, hepatic encephalopathy is described as a brain disorder in patients previously suffering from chronic liver ailments such as liver cirrhosis, hepatitis, and acute liver failure. If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis. Hepatic encephalopathy is categorized into three types, such as Type A (acute liver failure), Type B (portal systemic bypass without liver disease), and Type C (liver cirrhosis). The exact disease etiology is unknown, but the disease is triggered by the accumulation of toxins in the bloodstream as the diseased liver fails to neutralize the toxins. The clinical manifestations associated with hepatic encephalopathy are confusion, anxiety, lethargy, seizures, confused speech, personality changes, and poor body movements. The key factors driving the hepatic encephalopathy therapeutics market are the rising prevalence of liver disorders, the lack of nutrients in daily food intake, and increasing public health awareness resulting in early diagnosis and treatment.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

The diagnosis of hepatic encephalopathy includes blood tests, a liver function test, the detection of serum ammonia levels, and an encephalogram of the brain to measure the electrical activity of the brain. There are numerous therapeutic approaches to manage the severity of hepatic encephalopathy, but the reduction of plasma ammonia is the most preferred strategy. Lactulose is the first line of treatment, as it changes the acidity of the stool in order to reduce the production of ammonia by killing intestinal bacteria. Probiotics and thiamine are useful in the treatment of hepatic encephalopathy by increasing the expulsion of ammoniagenic bacteria by causing the bowel to get fermented by colonic bacteria to produce lactic and acetic acid. In 2010, the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract that produce ammonia.

The hepatic encephalopathy therapeutics market is classified as follows:

Treatment

  • Lactulose
  • Rifaximin
  • Neomycin
  • Probiotics
  • Thiamine

Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Key players identified for the hepatic encephalopathy market include:

ASKA Pharmaceutical Company Ltd., COSMO Pharmaceuticals, Fresenius Kabi AG, Mallinckrodt Pharmaceuticals, Lupin, Salix Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and other notable players

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

This report offers the following:

  • A market assessment is conducted by considering 2017 as the base year; the market size and compounded annual growth rate (CAGR) is given for the forecast period from 2018 to 2026.
  • For the scope of the report, an attractive investment proposition is given for the geography segments by understanding the prevailing market trends in the hepatic encephalopathy therapeutics market.
  • In the company profiles section, product portfolios of different manufacturers are listed. Vital information such as mergers and acquisitions, strategic collaborations, and the financial health of the key players is also included.

Frequently Asked Questions

What is the size of Hepatic Encephalopathy Therapeutics Market?

The market for Hepatic Encephalopathy Therapeutics Market is expected to reach US$ XX Mn By 2026.

What is the Hepatic Encephalopathy Therapeutics Market CAGR?

The Hepatic Encephalopathy Therapeutics Market is expected to see significant CAGR growth over the coming years, at XX%.

What is the Forecast period considered for Hepatic Encephalopathy Therapeutics Market?

The report is forecasted from 2018-2026.

What is the base year considered for Hepatic Encephalopathy Therapeutics Market?

The base year of this report is 2017.

Who are the major players in this market?

ASKA Pharmaceutical Company Ltd., COSMO Pharmaceuticals, Fresenius Kabi AG, Mallinckrodt Pharmaceuticals, Lupin, Salix Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc. are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN